OVID — Ovid Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636651 ·
Last close
$2.22
Market Cap
$414.34M
52W High
$2.99
52W Low
$2.16
ADV30
2,949,858
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -17,846,000 | -16,988,000 | 225,628,000 | 94,064,000 | 27,359,000 |
| Dec 2025 | 718,000 | — | -12,293,000 | 9,663,000 | 150,934,000 | 13,153,000 | 20,274,000 |
| Sep 2025 | 132,000 | — | -12,523,000 | -12,158,000 | 63,848,000 | 20,611,000 | 19,150,000 |
| Jun 2025 | 6,272,000 | — | -5,073,000 | -4,684,000 | 77,428,000 | 28,415,000 | 21,639,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,952,000
Investing CF
$-49,006,000
Financing CF
$164,176,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-338,701,000
Inventory
—
Receivables
—
ST Investments
$61,458,000
EBIT TTM
$-47,735,000
Pretax Income TTM
$-24,167,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,122,000
EBITDA
$-48,168,000
Free Cash Flow
$-20,829,376
Enterprise Value
$299,885,056
Total Cash
$155,522,000
Total Debt
$13,070,000
Shares Out
186,640,102
Trailing EPS
$-0.22
Book Value
$1.19
ROE
-18.8%
ROA
-19.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,252,000 | -42,439,000 | -17,414,000 | 150,934,000 | 20,274,000 | — | -38,334,000 |
| Dec 2024 | 566,000 | -61,885,000 | -26,433,000 | 92,167,000 | 23,941,000 | — | -55,956,000 |
| Dec 2023 | 392,000 | -59,281,000 | -52,339,000 | 144,027,000 | 56,229,000 | — | -45,781,000 |
| Dec 2022 | 1,502,748 | -55,547,651 | -54,169,029 | 155,265,814 | 22,993,250 | — | -55,227,127 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$173,000
NetIncome TTM
$-14,006,000
OpCashFlow TTM
$0
Assets (Latest)
$92,167,000
Forward EPS
$-0.45
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KMDA | KAMADA LTD | $411.94M | $7.14 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $418.09M | $6.40 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $408.11M | $0.38 | — |
| EVMN | Evommune, Inc. | $405.21M | $11.25 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $425.11M | $8.12 | — |
News headlines (Yahoo Finance, 1h cache)
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
2026-07-14 10:33 · Yahoo
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
2026-07-08 11:00 · Yahoo
Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-06-04 11:00 · Yahoo
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
2026-06-03 11:00 · Yahoo
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely
2026-05-14 10:51 · Yahoo
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-05-12 11:00 · Yahoo
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks
2026-05-10 04:01 · Yahoo
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
2026-04-08 12:00 · Yahoo
Ovid Therapeutics Q4 Earnings Call Highlights
2026-03-18 21:47 · Yahoo
Here's Why Ovid Therapeutics Stock Popped Higher Today
2026-03-18 18:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.